Combination of PARP and ATR inhibition has been shown to effectively target TP53/RB1-deficient PCa, resulting in significant growth inhibition when compared to PARPi monotherapy (p < 0.05) [114]. The gene discussed is TP53; the disease is posterior cortical atrophy.